Cargando…

The Mitochondrial Chaperone TRAP1 as a Candidate Target of Oncotherapy

Tumor necrosis factor receptor-associated protein 1 (TRAP1), a member of the heat shock protein 90 (Hsp90) chaperone family, protects cells against oxidative stress and maintains mitochondrial integrity. To date, numerous studies have focused on understanding the relationship between aberrant TRAP1...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Shulan, Wang, Xuanwei, Gan, Shuyuan, Tang, Xiaodong, Kang, Xianhui, Zhu, Shengmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870996/
https://www.ncbi.nlm.nih.gov/pubmed/33575209
http://dx.doi.org/10.3389/fonc.2020.585047
_version_ 1783648924499705856
author Xie, Shulan
Wang, Xuanwei
Gan, Shuyuan
Tang, Xiaodong
Kang, Xianhui
Zhu, Shengmei
author_facet Xie, Shulan
Wang, Xuanwei
Gan, Shuyuan
Tang, Xiaodong
Kang, Xianhui
Zhu, Shengmei
author_sort Xie, Shulan
collection PubMed
description Tumor necrosis factor receptor-associated protein 1 (TRAP1), a member of the heat shock protein 90 (Hsp90) chaperone family, protects cells against oxidative stress and maintains mitochondrial integrity. To date, numerous studies have focused on understanding the relationship between aberrant TRAP1 expression and tumorigenesis. Mitochondrial TRAP1 is a key regulatory factor involved in metabolic reprogramming in tumor cells that favors the metabolic switch of tumor cells toward the Warburg phenotype. In addition, TRAP1 is involved in dual regulation of the mitochondrial apoptotic pathway and exerts an antiapoptotic effect on tumor cells. Furthermore, TRAP1 is involved in many cellular pathways by disrupting the cell cycle, increasing cell motility, and promoting tumor cell invasion and metastasis. Thus, TRAP1 is a very important therapeutic target, and treatment with TRAP1 inhibitors combined with chemotherapeutic agents may become a new therapeutic strategy for cancer. This review discusses the molecular mechanisms by which TRAP1 regulates tumor progression, considers its role in apoptosis, and summarizes recent advances in the development of selective, targeted TRAP1 and Hsp90 inhibitors.
format Online
Article
Text
id pubmed-7870996
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78709962021-02-10 The Mitochondrial Chaperone TRAP1 as a Candidate Target of Oncotherapy Xie, Shulan Wang, Xuanwei Gan, Shuyuan Tang, Xiaodong Kang, Xianhui Zhu, Shengmei Front Oncol Oncology Tumor necrosis factor receptor-associated protein 1 (TRAP1), a member of the heat shock protein 90 (Hsp90) chaperone family, protects cells against oxidative stress and maintains mitochondrial integrity. To date, numerous studies have focused on understanding the relationship between aberrant TRAP1 expression and tumorigenesis. Mitochondrial TRAP1 is a key regulatory factor involved in metabolic reprogramming in tumor cells that favors the metabolic switch of tumor cells toward the Warburg phenotype. In addition, TRAP1 is involved in dual regulation of the mitochondrial apoptotic pathway and exerts an antiapoptotic effect on tumor cells. Furthermore, TRAP1 is involved in many cellular pathways by disrupting the cell cycle, increasing cell motility, and promoting tumor cell invasion and metastasis. Thus, TRAP1 is a very important therapeutic target, and treatment with TRAP1 inhibitors combined with chemotherapeutic agents may become a new therapeutic strategy for cancer. This review discusses the molecular mechanisms by which TRAP1 regulates tumor progression, considers its role in apoptosis, and summarizes recent advances in the development of selective, targeted TRAP1 and Hsp90 inhibitors. Frontiers Media S.A. 2021-01-26 /pmc/articles/PMC7870996/ /pubmed/33575209 http://dx.doi.org/10.3389/fonc.2020.585047 Text en Copyright © 2021 Xie, Wang, Gan, Tang, Kang and Zhu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xie, Shulan
Wang, Xuanwei
Gan, Shuyuan
Tang, Xiaodong
Kang, Xianhui
Zhu, Shengmei
The Mitochondrial Chaperone TRAP1 as a Candidate Target of Oncotherapy
title The Mitochondrial Chaperone TRAP1 as a Candidate Target of Oncotherapy
title_full The Mitochondrial Chaperone TRAP1 as a Candidate Target of Oncotherapy
title_fullStr The Mitochondrial Chaperone TRAP1 as a Candidate Target of Oncotherapy
title_full_unstemmed The Mitochondrial Chaperone TRAP1 as a Candidate Target of Oncotherapy
title_short The Mitochondrial Chaperone TRAP1 as a Candidate Target of Oncotherapy
title_sort mitochondrial chaperone trap1 as a candidate target of oncotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870996/
https://www.ncbi.nlm.nih.gov/pubmed/33575209
http://dx.doi.org/10.3389/fonc.2020.585047
work_keys_str_mv AT xieshulan themitochondrialchaperonetrap1asacandidatetargetofoncotherapy
AT wangxuanwei themitochondrialchaperonetrap1asacandidatetargetofoncotherapy
AT ganshuyuan themitochondrialchaperonetrap1asacandidatetargetofoncotherapy
AT tangxiaodong themitochondrialchaperonetrap1asacandidatetargetofoncotherapy
AT kangxianhui themitochondrialchaperonetrap1asacandidatetargetofoncotherapy
AT zhushengmei themitochondrialchaperonetrap1asacandidatetargetofoncotherapy
AT xieshulan mitochondrialchaperonetrap1asacandidatetargetofoncotherapy
AT wangxuanwei mitochondrialchaperonetrap1asacandidatetargetofoncotherapy
AT ganshuyuan mitochondrialchaperonetrap1asacandidatetargetofoncotherapy
AT tangxiaodong mitochondrialchaperonetrap1asacandidatetargetofoncotherapy
AT kangxianhui mitochondrialchaperonetrap1asacandidatetargetofoncotherapy
AT zhushengmei mitochondrialchaperonetrap1asacandidatetargetofoncotherapy